A. L. Waterhouse, Wine phenolics, Ann. N. Y. Acad. Sci, vol.957, pp.21-36, 2002.

M. Takaoka, Of the phenolic substances of white hellbore (veratrum grandiflorum loes, Fil.). J. Fac. Sci. Hokkaido Imp. Univ, vol.3, pp.1-16, 1940.

S. Nonomura, H. Kanagawa, and A. Makimoto, Chemical constituents of polygonaceous plants. I. Studies on the components of ko-j o-kon. (polygonum cuspidatum sieb. Et zucc.), Yakugaku zasshi J. Pharm. Soc. Jpn, vol.83, pp.254-264, 1963.

M. Jang, L. Cai, G. O. Udeani, K. V. Slowing, C. F. Thomas et al., Cancer chemopreventive activity of resveratrol, vol.275, pp.218-220, 1997.

E. J. Park and J. M. Pezzuto, The pharmacology of resveratrol in animals and humans, Biochim. Biophys. Acta, vol.1852, pp.1071-1113, 2015.

J. A. Baur and D. A. Sinclair, Therapeutic potential of resveratrol: The in vivo evidence, Nat. Rev. Drug Discov, vol.5, pp.493-506, 2006.

J. Tome-carneiro, M. Larrosa, A. Gonzalez-sarrias, F. A. Tomas-barberan, M. T. Garcia-conesa et al., Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence, Curr. Pharm. Des, vol.19, pp.6064-6093, 2013.

D. Naylor and A. J. , Cellular effects of resveratrol in skeletal muscle, Life Sci, vol.84, pp.637-640, 2009.

J. Hoeks and P. Schrauwen, Muscle mitochondria and insulin resistance: A human perspective, Trends Endocrinol. Metab, vol.23, pp.444-450, 2012.

J. A. Baur, K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin et al., Resveratrol improves health and survival of mice on a high-calorie diet, Nature, vol.444, pp.337-342, 2006.

M. Lagouge, C. Argmann, Z. Gerhart-hines, H. Meziane, C. Lerin et al., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha, Cell, vol.127, pp.1109-1122, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00188005

S. M. Houten, S. Violante, F. V. Ventura, and R. J. Wanders, The biochemistry and physiology of mitochondrial fatty acid beta-oxidation and its genetic disorders, Ann. Rev. Physiol, 2015.

J. P. Bonnefont, F. Djouadi, C. Prip-buus, S. Gobin, A. Munnich et al., Carnitine palmitoyltransferases 1 and 2: Biochemical, molecular and medical aspects, Mol. Asp. Med, vol.25, pp.495-520, 2004.

M. Deschauer, T. Wieser, and S. Zierz, Muscle carnitine palmitoyltransferase ii deficiency: Clinical and molecular genetic features and diagnostic aspects, Arch. Neurol, vol.62, pp.37-41, 2005.

N. Gregersen, B. S. Andresen, M. J. Corydon, T. J. Corydon, R. K. Olsen et al., Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship, Hum. Mutat, vol.18, pp.169-189, 2001.

J. P. Bonnefont, J. Bastin, A. Behin, and F. Djouadi, Bezafibrate for treatment of an inborn mitochondrial ?-oxidation defect, N. Engl. J. Med, vol.360, pp.838-840, 2009.

J. P. Bonnefont, J. Bastin, P. Laforet, F. Aubey, A. Mogenet et al., Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency, Clin. Pharmacol. Ther, vol.88, pp.101-108, 2010.

G. L. Arnold, J. Van-hove, D. Freedenberg, A. Strauss, N. Longo et al., A delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency, Mol. Genet. Metab, vol.96, pp.85-90, 2009.

U. Spiekerkoetter, J. Bastin, M. Gillingham, A. Morris, F. Wijburg et al., Current issues regarding treatment of mitochondrial fatty acid oxidation disorders, J. Inherit. Metab. Dis, vol.33, pp.555-561, 2010.

F. Djouadi and J. Bastin, Ppars as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders, J. Inherit. Metab. Dis, vol.31, pp.217-225, 2008.

D. Sardana, C. Zhu, M. Zhang, R. C. Gudivada, L. Yang et al., Drug repositioning for orphan diseases, Brief. Bioinform, vol.12, pp.346-356, 2011.

J. Bastin, A. Lopes-costa, and F. Djouadi, Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts, Hum. Mol. Genet, 2011.

V. Aires, D. Delmas, C. Le-bachelier, N. Latruffe, D. Schlemmer et al., Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts, Orphanet J. Rare Dis, vol.9, p.79, 2014.

J. L. Bitterman and J. H. Chung, Metabolic effects of resveratrol: Addressing the controversies, Cell. Mol. Life Sci, vol.72, pp.1473-1488, 2015.

S. S. Kulkarni and C. Canto, The molecular targets of resveratrol, Biochim. Biophys. Acta, vol.1852, pp.1114-1123, 2015.

P. J. Fernandez-marcos and J. Auwerx, Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis, Am. J. Clin. Nutr, vol.93, pp.884-890, 2011.

K. T. Howitz, K. J. Bitterman, H. Y. Cohen, D. W. Lamming, S. Lavu et al., Small molecule activators of sirtuins extend saccharomyces cerevisiae lifespan, Nature, vol.425, pp.191-196, 2003.

M. T. Borra, B. C. Smith, and J. M. Denu, Mechanism of human sirt1 activation by resveratrol, J. Biol. Chem, vol.280, pp.17187-17195, 2005.

M. Kaeberlein, T. Mcdonagh, B. Heltweg, J. Hixon, E. A. Westman et al., Substrate-specific activation of sirtuins by resveratrol, J. Biol. Chem, vol.280, pp.17038-17045, 2005.

M. Pacholec, J. E. Bleasdale, B. Chrunyk, D. Cunningham, D. Flynn et al., and resveratrol are not direct activators of SIRT1, J. Biol. Chem, vol.285, pp.8340-8351, 2010.

B. Dasgupta and J. Milbrandt, Resveratrol stimulates amp kinase activity in neurons, Proc. Natl. Acad. Sci, vol.104, pp.7217-7222, 2007.

X. Hou, S. Xu, K. A. Maitland-toolan, K. Sato, B. Jiang et al., Sirt1 regulates hepatocyte lipid metabolism through activating amp-activated protein kinase, J. Biol. Chem, vol.283, 2008.

N. L. Price, A. P. Gomes, A. J. Ling, F. V. Duarte, A. Martin-montalvo et al., Sirt1 is required for ampk activation and the beneficial effects of resveratrol on mitochondrial function, Cell Metab, vol.15, pp.675-690, 2012.

S. J. Park, F. Ahmad, A. Philp, K. Baar, T. Williams et al., Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting camp phosphodiesterases, Cell, vol.148, pp.421-433, 2012.

W. J. Koopman, P. H. Willems, and J. A. Smeitink, Monogenic mitochondrial disorders, N. Engl. J. Med, vol.366, pp.1132-1141, 2012.

F. Distelmaier, W. J. Koopman, . Van-den, L. P. Heuvel, R. J. Rodenburg et al., Mitochondrial complex i deficiency: From organelle dysfunction to clinical disease, Brain J. Neurol, vol.132, pp.833-842, 2009.

C. Viscomi, E. Bottani, and M. Zeviani, Emerging concepts in the therapy of mitochondrial disease, Biochim. Biophys. Acta, vol.1847, pp.544-557, 2015.

B. N. Finck and D. P. Kelly, PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease, J. Clin. Investig, vol.116, pp.615-622, 2006.

C. Handschin and B. M. Spiegelman, Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism, Endocr. Rev, vol.27, pp.728-735, 2006.

A. Lopes-costa, C. Le-bachelier, L. Mathieu, A. Rotig, A. Boneh et al., Beneficial effects of resveratrol on respiratory chain defects in patients' fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling, Hum. Mol. Genet, vol.23, pp.2106-2119, 2014.

J. L. Bowers, V. V. Tyulmenkov, S. C. Jernigan, and C. M. Klinge, Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta, Endocrinology, vol.141, pp.3657-3667, 2000.

L. J. Eichner and V. Giguere, Estrogen related receptors (errs): A new dawn in transcriptional control of mitochondrial gene networks, vol.11, pp.544-552, 2011.

A. Golubitzky, P. Dan, S. Weissman, G. Link, J. D. Wikstrom et al., Screening for active small molecules in mitochondrial complex i deficient patient's fibroblasts, reveals aicar as the most beneficial compound, PLoS ONE, vol.6, 2011.

B. De-paepe, K. Vandemeulebroecke, J. Smet, A. Vanlander, S. Seneca et al., Effect of resveratrol on cultured skin fibroblasts from patients with oxidative phosphorylation defects, Phytother. Res. PTR, vol.28, pp.312-316, 2014.

K. R. Polley, N. Jenkins, P. O'connor, and K. Mccully, Influence of exercise training with resveratrol supplementation on skeletal muscle mitochondrial capacity, Appl. Physiol. Nutr. Metab, vol.41, pp.26-32, 2016.

V. W. Dolinsky and J. R. Dyck, Experimental studies of the molecular pathways regulated by exercise and resveratrol in heart, skeletal muscle and the vasculature, Molecules, vol.19, pp.14919-14947, 2014.

P. Schrauwen and S. Timmers, Can resveratrol help to maintain metabolic health?, Proc. Nutr. Soc, vol.73, pp.271-277, 2014.

K. J. Nowak and K. E. Davies, Duchenne muscular dystrophy and dystrophin: Pathogenesis and opportunities for treatment, EMBO Rep, vol.5, pp.872-876, 2004.

F. Rahimov and L. M. Kunkel, The cell biology of disease: Cellular and molecular mechanisms underlying muscular dystrophy, J. Cell Biol, vol.201, pp.499-510, 2013.

N. Deconinck and B. Dan, Pathophysiology of duchenne muscular dystrophy: Current hypotheses. Pediatri. Neurol, vol.36, pp.1-7, 2007.

C. A. Timpani, A. Hayes, and E. Rybalka, Revisiting the dystrophin-atp connection: How half a century of research still implicates mitochondrial dysfunction in duchenne muscular dystrophy aetiology, vol.85, pp.1021-1033, 2015.

T. A. Partridge, The mdx mouse model as a surrogate for duchenne muscular dystrophy, FEBS J, vol.280, pp.4177-4186, 2013.

C. Webster, L. Silberstein, A. P. Hays, and H. M. Blau, Fast muscle fibers are preferentially affected in duchenne muscular dystrophy, Cell, vol.52, pp.503-513, 1988.

V. Ljubicic, M. Burt, and B. J. Jasmin, The therapeutic potential of skeletal muscle plasticity in duchenne muscular dystrophy: Phenotypic modifiers as pharmacologic targets, FASEB J, vol.28, pp.548-568, 2014.

C. Handschin, Y. M. Kobayashi, S. Chin, P. Seale, K. P. Campbell et al., PGC-1alpha regulates the neuromuscular junction program and ameliorates duchenne muscular dystrophy, Genes Dev, vol.21, pp.770-783, 2007.

Y. S. Hori, A. Kuno, R. Hosoda, M. Tanno, T. Miura et al., Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for duchenne muscular dystrophy, J. Pharmacol. Exp. Ther, vol.338, pp.784-794, 2011.

V. Ljubicic, M. Burt, J. A. Lunde, and B. J. Jasmin, Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1alpha axis, Am. J. Physiol. Cell Physiol, vol.307, pp.66-82, 2014.

J. T. Selsby, K. J. Morine, K. Pendrak, E. R. Barton, and H. L. Sweeney, Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse, PLoS ONE, vol.7, 2012.

E. Rybalka, C. A. Timpani, C. G. Stathis, A. Hayes, and M. B. Cooke, Metabogenic and nutriceutical approaches to address energy dysregulation and skeletal muscle wasting in duchenne muscular dystrophy, Nutrients, vol.7, pp.9734-9767, 2015.

C. Moorwood, O. Lozynska, N. Suri, A. D. Napper, S. L. Diamond et al., Drug discovery for duchenne muscular dystrophy via utrophin promoter activation screening, PLoS ONE, vol.6, 2011.

B. S. Gordon, D. C. Delgado-diaz, and M. C. Kostek, Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy, Clin. Nutr, vol.32, pp.104-111, 2013.

R. K. Olsen, N. Cornelius, and N. Gregersen, Genetic and cellular modifiers of oxidative stress: What can we learn from fatty acid oxidation defects?, Mol. Genet. Metab, vol.110, pp.31-39, 2013.

P. Roestenberg, G. R. Manjeri, F. Valsecchi, J. A. Smeitink, P. H. Willems et al., Pharmacological targeting of mitochondrial complex i deficiency: The cellular level and beyond, vol.12, pp.57-65, 2012.

F. Djouadi and J. Bastin, Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders, Cell Metab, vol.14, pp.715-716, 2011.

K. J. Pearson, J. A. Baur, K. N. Lewis, L. Peshkin, N. L. Price et al., Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span, Cell Metab, vol.8, pp.157-168, 2008.

C. B. Williams, M. C. Hughes, B. A. Edgett, T. D. Scribbans, C. A. Simpson et al., An examination of resveratrol's mechanisms of action in human tissue: Impact of a single dose in vivo and dose responses in skeletal muscle ex vivo, PLoS ONE, vol.9, 2014.

J. Yoshino, C. Conte, L. Fontana, B. Mittendorfer, S. Imai et al., Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance, Cell Metab, vol.16, pp.658-664, 2012.

S. Timmers, E. Konings, L. Bilet, R. H. Houtkooper, T. Van-de-weijer et al., Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans, Cell Metab, vol.14, pp.612-622, 2011.